Skip to content
Loading…
Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year,"…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.